BioCentury | Mar 19, 2019
Distillery Therapeutics

ALK2 inhibition for diffuse intrinsic pontine glioma

...testing the ALK2 inhibitor in models of ALK2-mutant DIPG. Sumitomo Dainippon Pharma Co. Ltd. has TP-0184...
BioCentury | Dec 30, 2016
Company News

Sumitomo, Tolero deal

...completed a Phase II trial to treat acute myelogenous leukemia (AML), and preclinical anemia candidate TP-0184...
Items per page:
1 - 2 of 2